BACPTDP: a water-soluble camptothecin pro-drug with enhanced activity in hypoxic/acidic tumors
- 222 Downloads
Hypoxia is a common feature of solid tumors. Up-regulation of hypoxia-inducing factor-1 (HIF-1) occurs in the majority of primary malignant tumors and in two-thirds of metastases, while most normal tissues are negative. HIF-1 induces the glycolytic phenotype, which creates an acidic extracellular microenvironment and associated pH gradient such that drugs that are weak acids are selectively taken up and retained in acidic tumors. 7-Butyl-10-amino-camptothecin (BACPT) is a prime example of an agent that can exploit the tumor pH gradient for enhanced selectivity.
This study profiles the antitumor activity of BACPT in vitro and its water-soluble dipeptide ester, BACPTDP, in vivo.
Antitumor activity was evaluated by proliferation assays in cancer cell lines and in murine xenograft models for human neuroblastoma (IMR-32), colon (HT29), ovarian (SK-OV-3), pancreatic (Panc-1), glioma (SF-295) and non-small-cell lung (NCI-H460) cancers.
BACPT had superior antiproliferative activity compared to established drugs in monolayer cultures of human neuroblastoma and pancreatic tumor cell lines and in 3-dimensional histocultures of colon and primary ovarian cancer. Antitumor activity of BACPTDP was comparable to irinotecan in IMR-32, HT29, SF-295 and NCI-H460 xenografts, significantly greater in SK-OV-3 and in Panc-1 where complete regressions were observed. Combination of BACPT with gemcitabine produced additive to synergistic interactions in Panc-1 cells that were independent of drug ratio and optimal when gemcitabine was administered 24 h prior to BACPT.
BACPTDP is a water-soluble camptothecin pro-drug that spontaneously generates the lipid-soluble active agent, BACPT. This topoisomerase inhibitor exploits solid tumor physiology for improved selectivity and activity against multiple tumor types with particular promise for use in treating pediatric neuroblastoma and pancreatic carcinoma.
KeywordsCamptothecin Glycolytic phenotype Xenograft models Growth inhibition Pancreatic cancer Drug combinations Median effect analysis
This work was supported in part by Small Business Innovation Research grant CA125871 from the National Cancer Institute.
- 3.Adams DJ, Black RD, Bolick NG, Richardson RA, Spasojevic I, Manikumar G, Wani MC, Dewhirst MW, Colvin OM (2005) Utilization of a fiber optic biosensor to assess uptake of a fluorescent camptothecin in human tumor xenografts. AACR Meet Abstracts 981-a-Google Scholar
- 4.Adams DJ, da Silva MW, Flowers JL, Kohlhagen G, Pommier Y, Colvin OM, Manikumar G, Wani MC (2006) Camptothecin analogs with enhanced activity against human breast cancer cells. I. Correlation of potency with lipophilicity and persistence in the cleavage complex. Cancer Chemother Pharmacol 57:135–144PubMedCrossRefGoogle Scholar
- 6.Adams DJ, Sandvold ML, Myhren F, Jacobsen TF, Giles F, Rizzieri DA (2008) Anti proliferative activity of ELACYT (TM) (CP-4055) in combination with cloretazine (VNP40101 M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells. Leuk Lymphoma 49:786–797PubMedCrossRefGoogle Scholar
- 7.Adams D, Brueim S, Maelandsmo G, Fodstad O, Myhren F, Sandvold M (2009) Drug combinations with gemcitabine 5’-elaidic acid ester (CP-4126) that exhibit synergistic activity in pancreatic cancer. Annual Meeting of the American Association for Cancer Research, AACR, Denver, COGoogle Scholar
- 17.Flowers JL, Hoffman RM, Driscoll TA, Wall ME, Wani MC, Manikumar G, Friedman HS, Dewhirst M, Colvin OM, Adams DJ (2003) The activity of camptothecin analogues is enhanced in histocultures of human tumors and human tumor xenografts by modulation of extracellular pH. Cancer Chemother Pharmacol 52:253–261PubMedCrossRefGoogle Scholar
- 23.Guiotto A, Canevari M, Orsolini P, Lavanchy O, Deuschel C, Kaneda N, Kurita A, Matsuzaki T, Yaegashi T, Sawada S, Veronese FM (2004) Synthesis, characterization, and preliminary in vivo tests of new poly(ethylene glycol) conjugates of the antitumor agent 10-amino-7-ethylcamptothecin. J Med Chem 47:1280–1289PubMedCrossRefGoogle Scholar
- 25.Hoffman RM (1991) 3-Dimensional histoculture—origins and applications in cancer-research. Cancer Cells Mon Rev 3:86–92Google Scholar
- 28.Kruszewski S, Kruszewska DM (2008) Affinity of new anticancer agent, 7-trimethylsilyl-ethyl-10-amino-camptothecin, to membranes and HSA determined by fluorescence spectroscopy methods. Optica Applicata 38:625–633Google Scholar
- 31.Onda T, Nakamura I, Seno C, Matsumoto S, Kitagawa M, Okamoto K, Nishikawa K, Suzuki M (2006) Superior antitumor activity of NK012, 7-ethyl-10-hydroxycamptothecin-incorporating micellar nanoparticle, to irinotecan. AACR Meet Abstracts 720-b-Google Scholar
- 32.Papish SW, Ramanathan RK, Pincus J, Hirmand M, Burris HA (2005) Patients rescued by crossover to rubitecan in phase III study of rubitecan capsules versus 5-FU in pancreatic cancer. J Clin Oncol 23:349SGoogle Scholar
- 33.Pencreach E, Guerin E, Nicolet C, Lelong-Rebel I, Voegeli AC, Oudet P, Larsen AK, Gaub MP, Guenot D (2009) Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1 alpha axis. Clin Cancer Res 15:1297–1307PubMedCrossRefGoogle Scholar
- 38.Singh B, Li RG, Xu L, Poluri A, Patel S, Shaha AR, Pfister D, Sherman E, Goberdhan A, Hoffman RM, Shah J (2002) Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head Neck J Sci Spec Head Neck 24:437–442Google Scholar
- 43.Wachsberger PR, Landry J, Storck C, Davis K, O’Hara MD, Owen CS, Leeper DB, Coss RA (1997) Mammalian cells adapted to growth at pH 6.7 have elevated HSP27 and are resistant to cisplatin. Int J Hypertherm 13:251–255 (discussion)Google Scholar